Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FS2 Cream for Mitigating Scarring in Burn Patients
NCT06807021Phase 3Recruiting
- Sponsor
- BirchBioMed
- Start
- Mar 2027
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Kynurenic acid in burn scar (2 arms), sponsored by BirchBioMed. Primary endpoint: Vancouver Scar Scale at 90 days. Planned start Mar 2027; status: recruiting.
02
Drugs
Kynurenic acid
03
Conditions
burn scar
Beyond the preview
Go deeper on NCT06807021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06807021.